Astellas Pharma (ALPMY)
(Delayed Data from OTC)
$9.47 USD
+0.01 (0.11%)
Updated Apr 18, 2024 03:59 PM ET
4-Sell of 5 4
B Value F Growth D Momentum D VGM
Cash flow Statements
Fiscal Year End for Astellas Pharma Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 995.00 | 1,286.00 | 1,309.00 | 2,251.00 |
Depreciation/Amortization & Depletion | NA | 795.00 | 653.00 | 655.00 | 609.00 |
Net Change from Assets/Liabilities | NA | -703.00 | -297.00 | -447.00 | -841.00 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 1,378.00 | 468.00 | 1,247.00 | 20.00 |
Net Cash From Operating Activities | NA | 2,464.00 | 2,110.00 | 2,764.00 | 2,037.00 |
Property & Equipment | NA | -274.00 | -248.00 | -221.00 | -315.00 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | -5.00 | -134.00 | -2,943.00 |
Investments | NA | 95.00 | 0.00 | 0.00 | 0.00 |
Other Investing Activities | NA | -456.00 | -258.00 | -383.00 | -318.00 |
Net Cash from Investing Activities | NA | -635.00 | -512.00 | -738.00 | -3,576.00 |
Uses of Funds
3/31/2024 | 3/31/2023 | 3/31/2022 | 3/31/2021 | 3/31/2020 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -455.00 | -416.00 | -83.00 | -485.00 |
Issuance (Repayment) of Debt | NA | -113.00 | -492.00 | -1,135.00 | 2,991.00 |
Increase (Decrease) Short-Term Debt | NA | -124.00 | -146.00 | -143.00 | -162.00 |
Payment of Dividends & Other Distributions | NA | -755.00 | -699.00 | -686.00 | -675.00 |
Other Financing Activities | NA | -24.00 | -21.00 | -20.00 | -8.00 |
Net Cash from Financing Activities | NA | -1,471.00 | -1,773.00 | -2,067.00 | 1,661.00 |
Effect of Exchange Rate Changes | NA | 99.00 | 91.00 | 111.00 | -55.00 |
Net Change In Cash & Equivalents | NA | 457.00 | -83.00 | 70.00 | 67.00 |
Cash at Beginning of Period | NA | 2,376.00 | 2,673.00 | 2,868.00 | 2,854.00 |
Cash at End of Period | NA | 2,833.00 | 2,590.00 | 2,938.00 | 2,921.00 |
Diluted Net EPS | NA | 0.41 | 0.55 | 0.58 | 0.95 |
Fiscal Year End for Astellas Pharma Inc falls in the month of March.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | 500.68 | 360.03 | 342.01 | 995.00 |
Depreciation/Amortization & Depletion | NA | 742.54 | 429.27 | 169.68 | 795.00 |
Net Change from Assets/Liabilities | NA | -769.30 | -547.38 | -353.23 | -703.00 |
Net Cash from Discontinued Operations | NA | NA | NA | 0.00 | 0.00 |
Other Operating Activities | NA | 209.44 | 96.75 | -69.42 | 1,378.00 |
Net Cash From Operating Activities | NA | 683.37 | 338.67 | 89.05 | 2,464.00 |
Property & Equipment | NA | -187.18 | -138.37 | -73.45 | -274.00 |
Acquisition/ Disposition of Subsidiaries | NA | -5,336.53 | -5,244.35 | 0.00 | 0.00 |
Investments | NA | NA | NA | 0.00 | 95.00 |
Other Investing Activities | NA | -77.06 | -22.28 | -16.33 | -456.00 |
Net Cash from Investing Activities | NA | -5,600.78 | -5,404.99 | -89.79 | -635.00 |
Uses of Funds
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | -72.99 | -74.05 | -78.34 | -455.00 |
Issuance (Repayment) of Debt | NA | 3,161.65 | 3,246.38 | 0.00 | -113.00 |
Increase (Decrease) Short-Term Debt | NA | 1,721.85 | 1,850.28 | 1,684.23 | -124.00 |
Payment of Dividends & Other Distributions | NA | -793.24 | -371.93 | -393.49 | -755.00 |
Other Financing Activities | NA | -51.98 | -26.59 | -7.60 | -24.00 |
Net Cash from Financing Activities | NA | 3,965.29 | 4,624.08 | 1,204.80 | -1,471.00 |
Effect of Exchange Rate Changes | NA | 116.66 | 146.60 | 143.87 | 99.00 |
Net Change In Cash & Equivalents | NA | -835.46 | -295.64 | 1,347.92 | 457.00 |
Cash at Beginning of Period | NA | 2,562.51 | 2,600.20 | 2,750.93 | 2,376.00 |
Cash at End of Period | NA | 1,727.05 | 2,304.55 | 4,098.86 | 2,833.00 |
Diluted Net EPS | NA | 0.07 | -0.01 | 0.13 | -0.19 |